98%
921
2 minutes
20
: The image guidance of choice for the combination therapy of radiofrequency ablation (RFA) and vertebral augmentation (VA) in the context of vertebral disease from spinal metastases are fluoroscopy and computer tomography (CT). Here, we aimed to assess the roles of both imaging modalities and if adoption of either would influence clinical outcomes of pain, physical function, and quality of life (QoL). RFA has been favored as a minimally invasive option for managing painful spinal metastases, and it is often coupled with VA to treat underlying osseous structural instability. This combination therapy of RFA with VA, which could be performed under CT or fluoroscopy, has in recent years been recognized as highly successful for pain control and functional restoration of metastatic spine lesions. : Our scoping review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). The databases accessed were Medline and Embase, and the time frame of the search was set from database inception to 2 January 2025. The inclusion eligibility included primary research studies utilizing clearly defined imaging modalities of interest with measurable clinical end points of pain, quality of life (QoL), analgesic use, or complications. : Twenty-two articles were identified after screening fifty-eight papers using the databases. Fluoroscopy alone was the more frequently adopted imaging modality ( = 17/22, 77.3%). Almost all of the papers, regardless of the imaging modality used, consistently demonstrated reduction in pain, improvement in QoL, as well as a decrease in analgesia use. Complications were present but had minimal clinical implications, aside from a single article which appeared to demonstrate significantly higher cement leak rates with a singular case of resultant paraplegia. : Fluoroscopy- and CT-guided RFA with VA have both proven to be efficacious in reducing patient discomfort and improving functionality while keeping risks of permanent neurological injuries to a minimum.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191964 | PMC |
http://dx.doi.org/10.3390/diagnostics15121463 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Neurosurgery Department, 10th Military Research Hospital and PolyClinic SPZOZ, Bydgoszcz, Poland.
Background: Pheochromocytoma (PCC) is a rare neuroendocrine tumor, with 10-15% of cases showing malignant behavior defined by metastatic spread, including exceptionally rare central nervous system (CNS) involvement. Brain metastases present unique diagnostic and therapeutic challenges due to their potential to impair neurological function. This study reports a case of malignant PCC (mPCC) with CNS metastases and a systematic review to clarify the clinical patterns, management strategies, and prognostic factors.
View Article and Find Full Text PDFAnn Afr Med
September 2025
Department of Pathology, Dr. Lal Path Labs, New Delhi, India.
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.
View Article and Find Full Text PDFNeuropathology
October 2025
Pathology Department, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.
Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.
View Article and Find Full Text PDFPract Radiat Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Re-irradiation of spinal metastases using stereotactic body radiotherapy (SBRT) presents clinical challenges, with limited patient outcomes data to guide decision-making. We report a retrospective, single-institutional experience of 107 lesions treated in 91 patients. 88 (72%) lesions were initially irradiated with conventional radiotherapy (median equivalent dose of 33Gy to the target, interquartile range, IQR: 23-35 Gy) with a median time to re-irradiation of 12 months (IQR: 4-21 months).
View Article and Find Full Text PDFEur Radiol Exp
September 2025
Gustave Roussy, UMR 9018-Metabolic and Systemic Aspects of Oncogenesis for New Therapeutic Approaches (METSY), Paris-Saclay University, 114 rue Edouard Vaillant, 94805, Villejuif, France.
Background: Electrochemotherapy (ECT) of vertebral metastasis is a new treatment option for metastasis that is not accessible to thermal ablation or radiotherapy. A numerical feasibility study has investigated the transpedicular approach for electrode insertion. We conducted a preclinical study to assess its safety.
View Article and Find Full Text PDF